The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $4.63

Today's change-0.11 -2.32%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $4.63

Today's change-0.11 -2.32%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Spectrum Pharmaceuticals Inc down (U.S.)$0.11

Spectrum Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$0.11 or 2.32% to (U.S.)$4.63. Over the last five days, shares have lost 6.65% and sit 3.46% above their 52-week low. This security has underperformed the S&P 500 by 24.92% during the last year.

Key company metrics

  • Open(U.S.) $4.72
  • Previous close(U.S.) $4.74
  • High(U.S.) $4.75
  • Low(U.S.) $4.54
  • Bid / Ask(U.S.) $1.00 / (U.S.) $6.39
  • YTD % change-23.22%
  • Volume945,394
  • Average volume (10-day)835,443
  • Average volume (1-month)786,562
  • Average volume (3-month)1,110,880
  • 52-week range(U.S.) $4.48 to (U.S.) $7.74
  • Beta1.09
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.76
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-30.23%

Although this company's net profit margin is negative, it is above the industry average and implies that Spectrum Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue29453952
Total other revenue--------
Total revenue29453952
Gross profit20393244
Total cost of revenue8678
Total operating expense45456053
Selling / general / administrative19232324
Research & development10101614
Depreciation / amortization77147
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-160-22-2
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-19-2-25-3
Income after tax-19-2-26-3
Income tax, total0000
Net income-19-2-26-3
Total adjustments to net income--------
Net income before extra. items-19-2-26-3
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-19-2-26-3
Inc. avail. to common incl. extra. items-19-2-26-3
Diluted net income-19-2-26-3
Dilution adjustment--------
Diluted weighted average shares66656566
Diluted EPS excluding extraordinary itemsvalue per share-0.28-0.04-0.39-0.05
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.28-0.04-0.39-0.05